Disc Medicine Inc(IRON-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low70.25
Day High72.44
Open:70.82
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Disc Medicine (IRON)
Tipranks
H.C. Wainwright Remains a Buy on Disc Medicine (IRON)
GlobeNewswire
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Tipranks
Analysts’ Top Healthcare Picks: Insmed (INSM), Harrow Health (HROW)
GlobeNewswire
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Tipranks
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)
Tipranks
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Vera Therapeutics (VERA)
GlobeNewswire
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)
MarketBeat
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
MarketBeat.com
Tipranks
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Tipranks
H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON)
Tipranks
Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)

Profile

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.